Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 96

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 96
---
 shareholder approval; •the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; •the expected benefits of the Merger; •the unexpected costs related to the proposed Merger; •the financial and business performance of NLS, including financial projections and business metrics and any underlying assumptions thereunder; •changes in NLS’s and Kadimastem’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; •the implementation, market acceptance and success of NLS’s and Kadimastem’s business model; •NLS’s and Kadimastem’s ability to scale in a cost -effectivemanner; •developments and projections relating to NLS’s and Kadimastem’s competitors and industry; •NLS’s and Kadimastem’s expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the rights of others; •expectations regarding the time during which NLS will be an EGC under the JOBS Act; •NLS’s and Kadimastem’s future capital requirements and sources and uses of cash; •NLS’s and Kadimastem’s ability to obtain funding for their operations; •NLS’s and Kadimastem’s business, expansion plans and opportunities; •NLS’s and Kadimastem’s management and board of directors; •the listing of NLS’s securities on Nasdaq; •geopolitical risk and changes in applicable laws or regulations; •fluctuations in exchange rates between the foreign currencies in which NLS and Kadimastem typically do business and the United States dollar; and •the outcome of any known and unknown litigation and regulatory proceedings. 22 These forward -lookingstatements are based on information available as of the date of this proxy statement/prospectus, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward -lookingstatements should not be relied upon as representing the views of NLS or Kadimastem as of any subsequent date, and neither NLS nor Kadimastem undertake any obligation to update forward -lookingstatements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward -lookingstatements in deciding how to grant your proxy or to instruct how your vote should be cast or how you